X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olodaterol (46) 46
tiotropium (41) 41
copd (39) 39
humans (38) 38
index medicus (34) 34
pulmonary disease, chronic obstructive - drug therapy (34) 34
respiratory system (33) 33
lung diseases, obstructive (26) 26
chronic obstructive pulmonary disease (25) 25
male (25) 25
treatment outcome (25) 25
female (24) 24
middle aged (24) 24
obstructive pulmonary-disease (24) 24
aged (23) 23
benzoxazines - administration & dosage (23) 23
pulmonary disease, chronic obstructive - physiopathology (22) 22
administration, inhalation (21) 21
bronchodilator agents - administration & dosage (21) 21
benzoxazines - adverse effects (20) 20
double-blind method (20) 20
adrenergic beta-2 receptor agonists - adverse effects (19) 19
bronchodilator agents - adverse effects (19) 19
fixed-dose combination (19) 19
original research (19) 19
benzoxazines - therapeutic use (18) 18
lung - drug effects (18) 18
adrenergic beta-2 receptor agonists - administration & dosage (17) 17
drug combinations (17) 17
forced expiratory volume (17) 17
lung - physiopathology (17) 17
pulmonary disease, chronic obstructive - diagnosis (17) 17
time factors (17) 17
bronchodilator agents - therapeutic use (16) 16
diseases of the respiratory system (16) 16
efficacy (16) 16
respiratory tract diseases (16) 16
tiotropium bromide - administration & dosage (15) 15
safety (14) 14
international journal of chronic obstructive pulmonary disease (13) 13
pharmacology & pharmacy (13) 13
tiotropium bromide - therapeutic use (13) 13
adrenergic beta-2 receptor agonists - therapeutic use (12) 12
quality of life (12) 12
respimat (12) 12
tiotropium bromide - adverse effects (12) 12
once-daily tiotropium (11) 11
care and treatment (10) 10
cross-over studies (10) 10
double-blind (10) 10
drug therapy (10) 10
gold 2-4 (10) 10
recovery of function (10) 10
severity of illness index (10) 10
adult (9) 9
analysis (9) 9
dosage and administration (9) 9
formoterol (9) 9
internal medicine (9) 9
nebulizers and vaporizers (9) 9
research (9) 9
review (9) 9
tiotropium plus olodaterol (9) 9
asthma (8) 8
drug therapy, combination (8) 8
exercise tolerance - drug effects (8) 8
indacaterol (8) 8
medicine & public health (8) 8
muscarinic antagonists - administration & dosage (8) 8
muscarinic antagonists - adverse effects (8) 8
pulmonary and respiratory medicine (8) 8
bronchodilator (7) 7
cholinergic antagonists - adverse effects (7) 7
drug administration schedule (7) 7
dyspnea (7) 7
laba (7) 7
long-acting beta-agonist (7) 7
long-acting muscarinic antagonist (7) 7
pharmacology/toxicology (7) 7
respiratory agents (7) 7
complications and side effects (6) 6
dose-response relationship, drug (6) 6
exacerbations (6) 6
human activities (6) 6
humanities (6) 6
lama (6) 6
long-acting β (6) 6
lung-function (6) 6
management (6) 6
mortality (6) 6
pharmacology (6) 6
salmeterol (6) 6
systematic review (6) 6
agonists (5) 5
benzoxazines - pharmacokinetics (5) 5
beta-agonists (5) 5
bronchodilators (5) 5
cardiology (5) 5
endocrinology (5) 5
exercise (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of COPD, ISSN 1176-9106, 10/2014, Volume 9, pp. 1133 - 1144
Background: Combining bronchodilators with different mechanisms of action may improve efficacy and reduce risk of side effects compared to increasing the dose... 
Olodaterol Respimat | Long-acting muscarinic antagonist | Bronchodilator | Long-acting beta2-agonist | Tiotropium HandiHaler | INDACATEROL | TRIALS | OBSTRUCTIVE PULMONARY-DISEASE | MANAGEMENT | long-acting beta2-agonist | RESPIRATORY SYSTEM | tiotropium HandiHaler (R) | long-acting muscarinic antagonist | bronchodilator | olodaterol Respimat (R) | Spirometry | Bronchodilator Agents - administration & dosage | United States | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Equipment Design | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Scopolamine Derivatives - administration & dosage | Female | Surveys and Questionnaires | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Pulmonary Disease, Chronic Obstructive - diagnosis | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Benzoxazines - adverse effects | Treatment Outcome | Lung - physiopathology | Muscarinic Antagonists - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium | Lung diseases, Obstructive | Research | Drug therapy, Combination | Drug therapy | Health aspects
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2014, Volume 9, pp. 629 - 645
Journal Article
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ISSN 1178-2005, 2019, Volume 14, pp. 1441 - 1453
Background: Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early stages of the disease, impacting... 
RESPIRATORY SYSTEM | noninterventional study | tiotropium | olodaterol | chronic obstructive pulmonary disease | physical activity | Tiotropium | non-interventional study
Journal Article
Journal Article
Advances in Therapy, ISSN 0741-238X, 9/2015, Volume 32, Issue 9, pp. 809 - 822
Journal Article
RESPIRATORY MEDICINE, ISSN 0954-6111, 10/2015, Volume 109, Issue 10, pp. 1312 - 1319
Background: Tiotropium + olodaterol improves lung function and symptoms compared to mono-therapies in chronic obstructive pulmonary disease (COPD). The OTEMTO... 
Tiotropium | CARDIAC & CARDIOVASCULAR SYSTEMS | Long-acting bronchodilator | EFFICACY | SAFETY | RESPIRATORY SYSTEM | RESPIMAT(R) | UMECLIDINIUM/VILANTEROL 62.5/25 MCG | COMBINATION | Olodaterol | COPD | Quality of life
Journal Article
RESPIRATORY RESEARCH, ISSN 1465-993X, 06/2016, Volume 17
Background: As lung function declines rapidly in the early stages of chronic obstructive pulmonary disease (COPD), the effects of bronchodilators in patients... 
Long-acting bronchodilator | GOLD 2-4 | EFFICACY | LUNG-FUNCTION | Severity | EXERCISE | ONCE-DAILY TIOTROPIUM | Tiotropium | OBSTRUCTIVE PULMONARY-DISEASE | Treatment history | RESPIRATORY SYSTEM | RESPIMAT(R) | FIXED-DOSE COMBINATION | OUTCOMES | IMPROVEMENTS | Olodaterol | COPD
Journal Article
RESPIRATORY RESEARCH, ISSN 1465-993X, 08/2015, Volume 16
Background: Olodaterol is a novel, inhaled long-acting beta(2)-agonist (LABA) with >24-h duration of action investigated in asthma and chronic obstructive... 
INDACATEROL | RESPIRATORY SYSTEM | BRONCHODILATION | Dose-finding | INHALED CORTICOSTEROIDS | RESPIMAT(R) | Long-acting beta-agonist | Olodaterol | AGONISTS | DURATION | Asthma | COPD
Journal Article
Journal Article
Respiratory Research, ISSN 1465-9921, 11/2017, Volume 18, Issue 1, pp. 196 - 10
Background: Long-acting bronchodilators are the cornerstone of pharmacologic treatment of COPD. The new combination of long-acting muscarinic antagonist (LAMA)... 
Tiotropium | Systematic review | Tiotropium/olodaterol fixed dose combination | Metanalysis | Olodaterol | COPD | MANAGEMENT | OBSTRUCTIVE PULMONARY-DISEASE | UMECLIDINIUM/VILANTEROL | RESPIRATORY SYSTEM | PLUS OLODATEROL | DOUBLE-BLIND | RESPIMAT(R) | FIXED-DOSE COMBINATION | FLUTICASONE | SEVERITY | Pulmonary Disease, Chronic Obstructive - diagnosis | Benzoxazines - administration & dosage | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Forced Expiratory Volume - physiology | Randomized Controlled Trials as Topic - methods | Humans | Administration, Inhalation | Treatment Outcome | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - administration & dosage | Tiotropium Bromide - administration & dosage | Spirometry - methods | Adrenergic beta-2 Receptor Agonists - administration & dosage | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Dosage and administration | Research | Drug therapy | Respiratory function | Acetylcholine receptors (muscarinic) | Prospero protein | Clinical trials | Pharmacology | Patients | Quality of life | Meta-analysis | Web portals | Studies | Literature reviews | Confidence intervals | Randomization | Dyspnea | Lungs | New combinations | Bronchodilators | Chronic obstructive pulmonary disease | Combined treatment | Clinical medicine | Safety | Respiration | olodaterol fixed dose combination
Journal Article
Drugs, ISSN 0012-6667, 1/2016, Volume 76, Issue 1, pp. 135 - 146
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2016, Volume 122, pp. 58 - 66
Abstract Background Long-term safety, particularly cardiovascular safety, is of special interest in maintenance treatment of chronic obstructive pulmonary... 
Pulmonary/Respiratory | Long-acting β-agonist | Safety | Long-acting muscarinic antagonist | COPD | Maintenance bronchodilator | CARDIAC & CARDIOVASCULAR SYSTEMS | OLODATEROL | PREVENTION | Long-acting beta-agonist | SALMETEROL | THERAPY | RESPIRATORY SYSTEM | COMORBIDITIES | EXACERBATIONS | TIOTROPIUM | RESPIMAT(R) | FIXED-DOSE COMBINATION | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Follow-Up Studies | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Muscarinic Antagonists - therapeutic use | Pulmonary Disease, Chronic Obstructive - epidemiology | Incidence | Cardiovascular Diseases - complications | Tiotropium Bromide - administration & dosage | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Cardiovascular Diseases - epidemiology | Female | Tiotropium Bromide - therapeutic use | Bronchodilator Agents - adverse effects | Benzoxazines - administration & dosage | Double-Blind Method | Comorbidity | Tiotropium Bromide - adverse effects | Administration, Inhalation | Benzoxazines - adverse effects | Pulmonary Disease, Chronic Obstructive - complications | Benzoxazines - therapeutic use | Muscarinic Antagonists - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Medical colleges | Respiratory agents | Lung diseases, Obstructive | Care and treatment | Safety and security measures | Analysis | Cardiac patients | Hypertension | Studies | Cardiac arrhythmia | Dictionaries | Heart attacks | Cardiovascular disease | Chronic obstructive pulmonary disease | Family medical history | Health risk assessment | Patients
Journal Article
Respiratory Research, ISSN 1465-9921, 07/2016, Volume 17, Issue 1, p. 77
Journal Article
Therapeutics and Clinical Risk Management, ISSN 1176-6336, 12/2015, Volume 11, pp. 1805 - 1811
Journal Article
International Journal of Chronic Obstructive Pulmonary Disease, ISSN 1176-9106, 10/2016, Volume 11, Issue 1, pp. 2191 - 2201
PURPOSE: The fixed-dose dual bronchodilator combination (FDC) of tiotropium and olodaterol showed increased effectiveness regarding lung function and... 
Cost–utility | Budget impact | Health economics | Cost-effectiveness | COPD | cost-effectiveness | UTILITY ANALYSIS | DAILY MAINTENANCE BRONCHODILATOR | SAFETY | INHALED CORTICOSTEROIDS | RISK | budget impact | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | PLUS OLODATEROL | EXACERBATIONS | ECONOMIC-IMPACT | RESPIMAT(R) | cost-utility | health economics | Bronchodilator Agents - therapeutic use | Drug Costs | Pulmonary Disease, Chronic Obstructive - mortality | Markov Chains | Cholinergic Antagonists - economics | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Models, Economic | Forced Expiratory Volume | Netherlands | Time Factors | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Tiotropium Bromide - therapeutic use | Budgets | Pulmonary Disease, Chronic Obstructive - economics | Cholinergic Antagonists - therapeutic use | Quality-Adjusted Life Years | Severity of Illness Index | Bronchodilator Agents - economics | Treatment Outcome | Lung - physiopathology | Disease Progression | Benzoxazines - therapeutic use | Tiotropium Bromide - economics | Medication Adherence | Adrenergic beta-2 Receptor Agonists - economics | Cost-Benefit Analysis | Lung - drug effects | Aged | Benzoxazines - economics | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Markov processes | Economic aspects | Lung diseases, Obstructive | Analysis
Journal Article
International Journal of COPD, ISSN 1176-9106, 10/2015, Volume 10, Issue 1, pp. 2347 - 2356
Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a progressive decline in lung function, is considered to be a leading... 
Bronchodilators | Tiotropium | Long-acting β2 agonists | Chronic obstructive pulmonary disease | Long-acting muscarinic antagonist | Olodaterol | MANAGEMENT | GOLD 2-4 | EFFICACY | HYPERINFLATION | bronchodilators | long-acting beta agonists | INHALER | olodaterol | tiotropium | SALMETEROL | ONCE-DAILY TIOTROPIUM | RESPIRATORY SYSTEM | RESPIMAT(R) | FIXED-DOSE COMBINATION | long-acting muscarinic antagonist | chronic obstructive pulmonary disease | COPD | Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Drug Costs | Bronchodilator Agents - administration & dosage | Cholinergic Antagonists - economics | Humans | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Tiotropium Bromide - pharmacokinetics | Forced Expiratory Volume | Tiotropium Bromide - administration & dosage | Adrenergic beta-2 Receptor Agonists - adverse effects | Benzoxazines - pharmacokinetics | Bronchodilator Agents - adverse effects | Cholinergic Antagonists - adverse effects | Pulmonary Disease, Chronic Obstructive - economics | Cholinergic Antagonists - pharmacokinetics | Bronchodilator Agents - economics | Pulmonary Disease, Chronic Obstructive - diagnosis | Benzoxazines - administration & dosage | Drug Administration Schedule | Tiotropium Bromide - adverse effects | Administration, Inhalation | Benzoxazines - adverse effects | Treatment Outcome | Lung - physiopathology | Cholinergic Antagonists - administration & dosage | Drug Synergism | Tiotropium Bromide - economics | Adrenergic beta-2 Receptor Agonists - economics | Bronchodilator Agents - pharmacokinetics | Cost-Benefit Analysis | Lung - drug effects | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Benzoxazines - economics | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Dosage and administration | Research | Drug therapy
Journal Article
Postgraduate Medicine, ISSN 0032-5481, 08/2018, Volume 130, Issue 6, pp. 515 - 522
Oral inhalation is the recommended delivery method of medications for the treatment of patients with chronic obstructive pulmonary disease (COPD). However,... 
patient preference | pressurized metered-dose inhaler | soft mist inhaler | lung deposition | safety | Chronic obstructive pulmonary disease | dry powder inhaler | efficacy | DEVICE | TIOTROPIUM PLUS OLODATEROL | SOFT MIST(TM) INHALER | MEDICINE, GENERAL & INTERNAL | SATISFACTION | IMPACT | AEROSOL | PREFERENCES | FIXED-DOSE COMBINATION | RESPIMAT INHALER
Journal Article